Tocilizumab
Treatment for Covid 19
Typical Dosage: 8 mg/kg IV (max 800 mg)
Effectiveness
80%
Safety Score
45%
Clinical Trials
86
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
8 mg/kg IV (max 800 mg)
Time to Effect
2-5 days
Treatment Duration
Single dose or two doses
Evidence Quality
HIGHNumber Needed to Treat (NNT)
28(Treat 28 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
75(Treat 75 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,500
Monitoring:$100
Side Effect Mgmt:$200
Total Annual:$1,800
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$12,000/QALY
QALYs Gained
0.04
Outcome-Based Costs
Cost per Responder
$2,769.23
Comparison vs Dexamethasone
Cost Difference
+$1,500/year
More expensive
QALY Difference
+0.02 QALYs
Better outcomes
Dominance
No dominance
Tocilizumab Outcomes
for Covid 19
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+65%
Common Side Effects
Serious infections
+8%
Neutropenia
+7%
Elevated liver enzymes
+6%
GI perforation
+0.5%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
9 completed trials for Tocilizumab in Covid 19
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia
NCT04363736COMPLETEDPHASE2
97 participants
INTERVENTIONAL
Phoenix, United States +23 more
Started: May 5, 2020
Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis
NCT04331795COMPLETEDPHASE2
32 participants
INTERVENTIONAL
Chicago, United States
Started: Apr 4, 2020
TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience
NCT04730323COMPLETEDPHASE4
93 participants
INTERVENTIONAL
Lahore, Pakistan
Started: May 12, 2020
Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia
NCT04445272COMPLETEDPHASE2
495 participants
INTERVENTIONAL
Palma de Mallorca, Spain +41 more
Started: May 22, 2020
Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial
NCT04678739COMPLETEDPHASE3
205 participants
INTERVENTIONAL
Chittagong, Bangladesh +3 more
Started: Aug 15, 2020
The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol
NCT04349410COMPLETEDPHASE2, PHASE3
1.8K participants
INTERVENTIONAL
Los Angeles, United States
Started: Apr 11, 2020
A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19
NCT05164133COMPLETEDPHASE1
2 participants
INTERVENTIONAL
Los Angeles, United States +24 more
Started: Jun 10, 2022
Tocilizumab Versus Baricitinib in Patients With Severe COVID-19
NCT05082714COMPLETEDNA
251 participants
INTERVENTIONAL
Pátrai, Greece
Started: Oct 20, 2021
The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
NCT05035589COMPLETED
100 participants
OBSERVATIONAL
Msida, Malta
Started: Sep 20, 2021
Showing 20 of 86 total trials